March 10, 2020Open Access

Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction with End-Stage of Renal Disease

SLSeonhwa LeeNational Cancer Center JOJaewon OhMilken Institute HKHyoeun KimAlbany State University

Structured PICO

Does sacubitril/valsartan improve hsTnT, sST2 levels, and LVEF in patients with HFrEF and end-stage renal disease on dialysis?

Population

Patients with heart failure with reduced ejection fraction (HFrEF) and end-stage renal disease (ESRD) on dialysis

Intervention

Sacubitril/valsartan

Outcome

hsTnT levels, sST2 levels, and left ventricular ejection fraction (LVEF)surrogate

Sacubitril/valsartan may be safe and effective for improving cardiac biomarkers and LVEF in patients with HFrEF and end-stage renal disease on dialysis.

Abstract

We found that SV could safely reduce the hsTnT and sST2 levels and improve LVEF in HFrEF patients with ESRD. As far as we know, this is the first study to show the efficacy and safety of SV in HFrEF with ESRD on dialysis. Larger prospective, long-term follow-up study should be warranted.

Ask AI

Helpful

Bookmark

View Full Paper